Myocardial Injury After Radical Nephrectomy
Launched by SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST · Jul 17, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called myocardial injury, which can happen after a major surgery to remove a kidney due to cancer. This heart damage, known as MINS, can occur without the usual symptoms like pain and can only be detected through a simple blood test. The trial aims to find out how many patients experience MINS after kidney removal surgery and whether different surgical methods (like open surgery, keyhole surgery, or robotic surgery) affect the risk of developing this condition.
To participate, you need to be an adult aged 18 or older, scheduled for a radical nephrectomy for suspected kidney cancer, and able to give informed consent. The study will involve blood tests on the day of and the day after your surgery, which will be part of your regular hospital tests. Researchers will also check in with you about your quality of life and any heart or breathing problems about 90 days after the surgery. By gathering this information, the goal is to better understand MINS and help future patients avoid this complication.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Adult patients (aged 18 and above)
- • Undergoing a radical nephrectomy (either laparoscopic or robotic) for suspected renal cancer
- • Stage \<T3a
- • Can provide informed consent
- • Exclusion Criteria
- • Patients under 18
- • Undergoing partial nephrectomy
- • Undergoing radical nephrectomy not for suspected renal cancer
- • Unable to provide informed consent
About Sheffield Teaching Hospitals Nhs Foundation Trust
Sheffield Teaching Hospitals NHS Foundation Trust is a leading healthcare institution in the UK, dedicated to delivering high-quality patient care, advancing medical research, and fostering education and training in the health sector. As a prominent sponsor of clinical trials, the Trust collaborates with various stakeholders to facilitate innovative research initiatives that aim to improve treatment outcomes and enhance patient safety. With a commitment to excellence, the organization leverages its extensive clinical expertise and resources to support the development of new therapies and interventions, ultimately contributing to the advancement of healthcare practices both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sheffield, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported